患者对细胞癌辅助治疗的偏好:一个离散选择实验
Shawna R Calhoun1, Caroline Vass2, Kelley Myers3
1Merck & Co., Inc, MRL, Rahway, NJ, USA.
Future oncology (London, England)
|February 12, 2025
概括
患有细胞癌 (RCC) 的患者优先考虑改善存活率和减少副作用的治疗方法. 患者和医生之间的讨论对于个性化辅助RCC治疗决策至关重要.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 患者报告的结果
背景情况:
- 对细胞癌 (RCC) 的辅助治疗决定需要了解患者的偏好.
- 量化患者优先事项对于在RCC管理中共享决策至关重要.
研究的目的:
- 量化患者对辅助细胞癌 (RCC) 治疗各种特征的偏好.
- 为了确定患者在治疗的好处和风险之间的权衡.
主要方法:
- 离散选择实验涉及250名RCC患者.
- 使用随机参数逻辑和潜在类模型进行分析.
主要成果:
- 患者优先考虑增加无疾病和整体存活时间 (OS) 的治疗方法.
- 主要偏好包括不太频繁的服用,不同时服用药物,更短的持续时间和更低的副作用风险.
- 患者表现出愿意接受某些副作用 (腹,头,疲劳) 以改善生存结果.
- 潜在类分析显示,根据治疗优先级,有三个不同的患者组.
结论:
- 患者对辅助RCC治疗的偏好存在显著的异质性.
- 个性化患者与医生的讨论对于优化RCC治疗选择至关重要.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.5K
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
